Celator announces data, recommendation to continue CPX-351 Phase 3 study Celator Pharmaceuticals announced that the independent Data and Safety Monitoring Board for the Company's Phase 3 clinical study of CPX-351 Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen as first-line therapy in older patients with high-risk acute myeloid leukemia has completed a planned safety review and recommended that the study should continue as planned without any modifications. The primary efficacy endpoint of the study is overall survival. The study is being conducted in the U.S. and Canada, with more than 40 leading cancer centers participating.
Celator Pharmaceuticals reports Q4 EPS (7c), consensus (16c) Cash and cash equivalents as of December 31, 2014 were $32.4M, compared to $23.6M as of December 31, 2013. The following are expected milestones for the company: CPX-351 Phase 3 study: 2Q15 – Induction response rate; 1Q16 – Overall survival data. Technology platform: 3Q15 – information packages for novel combinations.